Trethera News

Trethera To Present Optic Neuritis Research at Los Angeles Bioscience Ecosystem Summit 2026

Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors

Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients

Trethera to Highlight Clinical Momentum and Indication Expansion at Biocom Global Partnering & Investor Conference

Trethera will present at the 16th Annual Biocom Global Partnering & Investor Conference following completion of its Phase 1 solid tumor dose escalation trial. The company will highlight TRE-515’s clinical momentum, Fast Track status, and upcoming indication expansion plans.

Trethera Receives $2.7 Million NIH Grant, Validating the Potential of First-in-Class TRE-515 to Overcome KRAS Inhibitor Resistance in Lung Cancer

Trethera receives a $2.7M NIH grant to study TRE-515 in combination with KRAS inhibitors for lung cancer. The funding supports preclinical studies aimed at overcoming resistance in NSCLC by targeting the nucleoside salvage pathway, with strong rationale and favorable early safety data.